Suven Life Scie.

Who are the top shareholders of the Suven Life Scie.?

The top shareholders of Suven Life Sciences include Jasti Property And Equity Holdings Private Limited with 69.56%, individual investors with 24.04%, and foreign institutional investors holding 0.25%. There are no pledged promoter holdings or significant public shareholders.

The top shareholders of Suven Life Sciences primarily include the promoters, with Jasti Property And Equity Holdings Private Limited being the largest shareholder, holding 69.56% of the company. There are also individual investors who collectively own 24.04% of the shares. Additionally, mutual funds hold a very small percentage (0.01%) across three schemes, and foreign institutional investors (FIIs) have a combined holding of 0.25% through 14 different entities. There are no pledged promoter holdings or significant public shareholders noted.

What is the bonus history of the Suven Life Scie.?

Suven Life Sciences Ltd has a bonus history that includes a 1:1 bonus issue announced on March 23, 2007, with a record date of April 2, 2007, allowing shareholders to receive an additional share for each share held.

Suven Life Sciences Ltd has a bonus history that includes a 1:1 bonus issue. This was announced with an ex-date of March 23, 2007, and the record date for this bonus was April 2, 2007. This means that shareholders on record as of the record date received an additional share for every share they held.

Has Suven Life Scie. declared dividend?

Yes, Suven Life Sciences Ltd has declared a dividend of 150% (₹1.5 per share) with an ex-date of February 14, 2019. However, the dividend yield is 0%, indicating that returns are mainly from price appreciation rather than dividend income.

Suven Life Sciences Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 150%<BR>- Amount per share: 1.5<BR>- Ex-date: 14 Feb 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 47.35%, the dividend return was 0%, resulting in a total return of 47.35%.<BR><BR>For the 1-year period, the price return was 135.02%, the dividend return was 0%, leading to a total return of 135.02%.<BR><BR>Over the 2-year period, the price return was 267.93%, with a dividend return of 0%, culminating in a total return of 267.93%.<BR><BR>In the 3-year period, the price return was 176.98%, the dividend return was 0%, which resulted in a total return of 176.98%.<BR><BR>For the 4-year period, the price return was 133.95%, the dividend return was 0%, giving a total return of 133.95%.<BR><BR>In the 5-year period, the price return was 516.17%, with a dividend return of 0%, resulting in a total return of 516.17%.<BR><BR>Overall, while Suven Life Sciences Ltd has declared a significant dividend, the dividend yield remains at 0%, indicating that the returns are primarily driven by price appreciation rather than dividend income. The total returns over various periods show strong performance, particularly over the longer term.

Who are the peers of the Suven Life Scie.?

Suven Life Sciences' peers include Syngene Intl., Dr Lal Pathlabs, and Poly Medicure, among others. Suven Life Sciences has the highest 1-year return at 160.99%, while it has below-average management risk and capital structure compared to its peers.

Peers: The peers of Suven Life Scie. are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Vimta Labs, Laxmi Dental, Krsnaa Diagnost., Tarsons Products, and Suraksha Diagno.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and the rest. Average management risk is present at Vimta Labs and Krsnaa Diagnost., while Below Average management risk is noted for Suven Life Scie. and Tarsons Products. Growth is Excellent at Vimta Labs and Laxmi Dental, Average at Poly Medicure and Indegene, and Below Average at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Suven Life Scie., Krsnaa Diagnost., and Tarsons Products. Capital Structure is Excellent at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and Krsnaa Diagnost., Good at Laxmi Dental and Tarsons Products, and Below Average at Suven Life Scie.<BR><BR>Return Snapshot: Suven Life Scie. has the highest 1-year return at 160.99%, while Syngene Intl. has the lowest at -3.51%. Compared to its peers, Suven Life Scie. significantly outperforms them in 1-year returns. Additionally, Krsnaa Diagnost. and Tarsons Products have negative six-month returns.

Is Suven Life Scie. overvalued or undervalued?

As of October 14, 2020, Suven Life Sciences is considered overvalued and risky due to negative financial ratios, including a PE ratio of -30.02 and an EV to EBITDA of -28.75, despite a strong historical return of 128.61% over the past year.

As of 14 October 2020, the valuation grade for Suven Life Sciences moved from expensive to risky. The company is currently considered overvalued based on its financial ratios, which include a PE ratio of -30.02, an EV to EBITDA of -28.75, and a ROCE of -343.32%. These figures indicate significant financial distress and a lack of profitability, which is concerning for potential investors.<BR><BR>In comparison to its peers, Suven Life Sciences stands out negatively; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE of 22.99 and an EV to EBITDA of 15.93. These comparisons highlight that Suven Life Sciences is not only underperforming but also carries a much higher risk profile. Despite a strong historical performance with a 1Y return of 128.61% compared to the Sensex's 7.61%, the current valuation metrics suggest that the stock is overvalued and may not be a prudent investment at this time.

Who are in the management team of Suven Life Scie.?

As of March 2023, the management team of Suven Life Sciences includes Venkateswarlu Jasti (Chairman & CEO), Sudha Rani Jasti (Whole-time Director), Seyed E Hasnain (Director), and several Independent Directors: M Gopalakrishna, Santanu Mukherjee, J A S Padmaja, along with Shrenik Soni (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

As of March 2023, the management team of Suven Life Sciences includes:<BR><BR>1. Venkateswarlu Jasti - Chairman & CEO<BR>2. Sudha Rani Jasti - Whole-time Director<BR>3. Seyed E Hasnain - Director<BR>4. M Gopalakrishna - Independent Director<BR>5. Santanu Mukherjee - Independent Director<BR>6. J A S Padmaja - Independent Director<BR>7. Shrenik Soni - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Suven Life Scie. do?

Suven Life Sciences Ltd is a mid-cap healthcare services company, incorporated in 1989, with recent net sales of 15 Cr and a net profit of -439 Cr as of March 2025. The company focuses on pharmaceutical development and has a market cap of INR 6,329 Cr.

Overview:<BR>Suven Life Sciences Ltd operates in the healthcare services industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was incorporated in March 1989 and changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September 2003. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 15 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -439 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 6,329 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.55 <BR>Return on Equity: -146.14% <BR>Price to Book: 58.69<BR><BR>Contact Details:<BR>Address: #8-2-334 SDE Serene Chambers, 6 th Floor Road No 5 Avenue 7 Hyderabad Telangana : 500034 <BR>Tel: 91-40-23541142/3311/3315 <BR>Email: info@suven.com <BR>Website: http://www.suven.com

How big is Suven Life Scie.?

As of 24th July, Suven Life Sciences Ltd has a market capitalization of 6,158.00 Cr, with Net Sales of 6.66 Cr and a Net Profit loss of 160.74 Cr over the latest 4 quarters. Shareholder's Funds are 270.04 Cr, and Total Assets are valued at 284.90 Cr.

As of 24th July, Suven Life Sciences Ltd has a market capitalization of 6,158.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 6.66 Cr. However, it faced a loss of 160.74 Cr in Net Profit during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2024. Shareholder's Funds stand at 270.04 Cr, while Total Assets are valued at 284.90 Cr.

How has been the historical performance of Suven Life Scie.?

Suven Life Sciences has experienced a significant decline in financial performance, with net sales dropping from 285.67 crore in March 2019 to 6.66 crore in March 2025, and increasing losses leading to a net profit of -160.75 crore in March 2025. The company faces ongoing operational challenges, reflected in negative cash flow and reduced asset values.

Answer:<BR>The historical performance of Suven Life Sciences has shown a significant decline in key financial metrics over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Suven Life Sciences reported net sales of 6.66 crore in March 2025, a sharp decrease from 11.69 crore in March 2024 and 13.54 crore in March 2023, continuing a downward trend from 285.67 crore in March 2019. The total operating income mirrored this decline, dropping to 6.66 crore in March 2025 from 11.69 crore in the previous year. The company's total expenditure, excluding depreciation, rose to 172.43 crore in March 2025, up from 139.70 crore in March 2024, leading to an operating profit (PBDIT) of -165.77 crore in March 2025, worsening from -128.01 crore in March 2024. Consequently, the profit before tax also deteriorated to -160.75 crore in March 2025, compared to -106.08 crore in March 2024. The net profit for March 2025 was reported at -160.75 crore, a decline from -105.08 crore in March 2024. The company's total assets decreased to 135.18 crore in March 2025 from 284.90 crore in March 2024, while total liabilities also fell to 135.18 crore from 284.90 crore in the same period. Cash flow from operating activities remained negative at -154.00 crore in March 2025, indicating ongoing operational challenges. Overall, Suven Life Sciences has faced significant financial difficulties, reflected in declining sales, increasing losses, and reduced asset values over the years.

Is Suven Life Scie. technically bullish or bearish?

As of December 3, 2025, the technical trend has shifted to mildly bearish, indicated by bearish signals from the weekly MACD and KST, daily moving averages, and Bollinger Bands, despite a bullish weekly RSI and strong year-to-date performance.

As of 3 December 2025, the technical trend has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish signals, while the daily moving averages confirm a bearish outlook. The weekly RSI remains bullish, but the overall technical indicators suggest a weakening trend. The Bollinger Bands show a mildly bearish signal on the weekly timeframe, further supporting the bearish stance. Despite a strong performance year-to-date and over longer periods, the recent trend shift indicates caution in the near term.

When is the next results date for Suven Life Sciences Ltd?

The next results date for Suven Life Sciences Ltd is January 29, 2026.

The next results date for Suven Life Sciences Ltd is scheduled for January 29, 2026.

Are Suven Life Sciences Ltd latest results good or bad?

Suven Life Sciences Ltd's latest results are concerning, with a net profit of -₹101.92 crores and a revenue drop of 64.20% year-on-year, indicating severe operational challenges and a bearish stock trend. Investors should exercise caution due to the company's significant losses and high market valuation relative to its sales.

Suven Life Sciences Ltd's latest results are quite concerning. In the third quarter of FY26, the company reported a net profit of -₹101.92 crores, which reflects a significant decline of 50.06% compared to the previous quarter. Revenue also plummeted to just ₹0.92 crores, marking a staggering 64.20% decrease year-on-year and a 50.80% drop quarter-on-quarter. This represents the lowest quarterly revenue in recent history, raising serious questions about the sustainability of its business model.<BR><BR>The operating margin is alarmingly negative at -8670.65%, indicating severe operational challenges. With a market capitalization of ₹2,975 crores, the company is trading at an extremely high valuation relative to its sales, which is 475.22 times its revenue. This disconnect between market valuation and operational performance is troubling.<BR><BR>Additionally, the stock has faced relentless selling pressure, declining 53.62% over the past six months and 32.65% in the last quarter. The technical indicators suggest a bearish trend, with the stock trading below all key moving averages.<BR><BR>Overall, the financial performance indicates a company in distress, with accelerating losses, a collapse in revenue, and a lack of clear path to recovery. Investors should approach this situation with caution.

Should I buy, sell or hold Suven Life Sciences Ltd?

Why is Suven Life Sciences Ltd falling/rising?

As of 02-Feb, Suven Life Sciences Ltd's stock price has declined to Rs 137.40, reflecting a drop of -1.36%. This decline is driven by poor financial performance, decreased investor interest, and negative market sentiment, indicating a bearish trend for the stock.

As of 02-Feb, Suven Life Sciences Ltd is experiencing a decline in its stock price, currently at Rs 137.40, which reflects a change of -1.9 (-1.36%). This drop can be attributed to several factors highlighted in the recent performance data. <BR><BR>Today, the stock has underperformed its sector by -1.29%, indicating a weaker performance relative to its peers. Additionally, it has fallen after two consecutive days of gains, suggesting a potential trend reversal. The stock reached an intraday low of Rs 132.2, marking a significant decline of -5.1%. The weighted average price indicates that more volume was traded closer to this low price, further emphasizing the downward pressure on the stock.<BR><BR>Investor participation has also decreased, with delivery volume dropping by -9.48% compared to the 5-day average, which may reflect waning interest among investors. Although the stock is liquid enough for trading, its moving averages show that it is currently higher than the 5-day moving average but lower than the 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>Moreover, the company's financial health raises concerns, as it has reported operating losses and negative results for the last six consecutive quarters. The net sales have decreased at an annual rate of -19.24%, and the operating profit has plummeted by -204.12% over the past five years. The company's ability to service its debt is also weak, with a poor EBIT to Interest ratio of -165.17. These factors contribute to the perception of the stock as risky, especially given that while it generated a return of 5.45% over the past year, its profits have fallen by -91.6%.<BR><BR>In summary, the combination of declining investor interest, poor financial performance, and negative market sentiment has led to the current fall in the stock price of Suven Life Sciences Ltd.

Which are the latest news on Suven Life Scie.?